Core Viewpoint - Maipu Medical plans to acquire 100% equity of Yijie Medical through a combination of share issuance and cash payment, aiming to expand its product offerings in the neurointerventional medical device market [1][2]. Group 1: Company Overview - Maipu Medical specializes in developing high-performance implantable medical devices using advanced manufacturing technology, covering key products needed for craniotomy surgeries [1]. - Yijie Medical focuses on the research, design, and sales of neurointerventional medical devices, including neurointerventional catheters and balloon dilation catheters [1]. Group 2: Market Potential - The neurovascular interventional medical device market in China grew from 3.2 billion yuan in 2017 to 6.7 billion yuan in 2022, with a compound annual growth rate (CAGR) of 15.7% [2]. - It is projected that the market size will reach 43.2 billion yuan by 2028, with a CAGR of 36.5% [2]. Group 3: Financial Performance and Challenges - Yijie Medical is expected to generate revenues of 11.94 million yuan and 24.41 million yuan in 2023 and 2024, respectively, but will incur net losses of 29.51 million yuan and 26.16 million yuan [3]. - The company faces significant challenges due to market competition and regulatory pressures, which may adversely affect its operations if strategic adjustments are not made [3]. Group 4: Market Reaction - Following the announcement of the acquisition, Maipu Medical's stock price fell by 8.31% to 58.25 yuan per share after resuming trading [4].
迈普医学拟“完控”易介医疗，布局神经介入领域